C2i Genomics offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor's DNA. C2i's liquid biopsy is a tool for cancer tumor monitoring. It works by identifying subtle changes in genetic patterns across the entire tumor. Based on bioinformatics and artificial intelligence, it compares thousands of data points obtained from patients' periodic liquid biopsy blood tests to their own baseline of sequenced tumor tissue and whole-genome analysis. The unique pattern generated is converted to a cancer burden score, making cancer more predictable and manageable. The company's ultra-sensitive liquid biopsy assay allows physicians to monitor and improve their patients' treatment response and detect disease recurrence months and years before current monitoring methods are able to provide results.